Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma

Drugs

Volumn 65, Issue 2, 2005, Pages 167-178

  Hartmann, Jörg Thomas ^a,c   Patel, Shreyaskumar ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTIMETABOLITE; BROSTALLICIN; CYTOTOXIC AGENT; DACARBAZINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPOTHILONE B; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; IXABEPILONE; NAVELBINE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; STEM CELL FACTOR; TAXANE DERIVATIVE; TEMOZOLOMIDE; TOPOTECAN; TRABECTEDIN; TROFOSFAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL PROTOCOL; CLINICAL TRIAL; DESMOPLASTIC SMALL ROUND CELL TUMOR; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; EWING SARCOMA; FIBROSARCOMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KAPOSI SARCOMA; LIPOSARCOMA; META ANALYSIS; METASTASIS; MULTIMODALITY CANCER THERAPY; NEUROECTODERM TUMOR; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEOMORPHIC ADENOMA; PLEOMORPHIC SARCOMA; REVIEW; RHABDOMYOSARCOMA; SALVAGE THERAPY; SEPSIS; SMALL CELL SARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; SYSTEMATIC REVIEW; TREATMENT FAILURE; VASCULAR SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; NEOPLASM METASTASIS; SALVAGE THERAPY; SARCOMA;

VINCA;

EID: 12344318080     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565020-00002     Document Type: Review

References (72)

1. Patel SR. New agents in the treatment of soft-tissue sarcomas. Expert Opin Investig Drugs 2000; 9: 1545-51
2. Patel SR, Chu P, Vadhan-Raj S. Differential responsiveness of leiomyosarcoma (leio) arising at different sites to doxorubicin-based chemotherapy [abstract], Proc Am Assoc Cancer Res 1997; 38: 7
3. Bertuzzi A, Castagna L, Nozza A, et al. High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. J Clin Oncol 2002; 20: 2181-8
4. Kushner BH, LaQuaglia MP, Wollner N, et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 1996; 14: 1526-31
5. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5: 840-50
6. Lopez M, Vici P, Di Lauro L, et al. Increasing single epirubicin doses in advanced soft tissue sarcomas. J Clin Oncol 2002; 20: 1329-34
7. Cure H, Krakowski I, Adenis A, et al. Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group. Eur J Cancer 1998; 34: 422-3
8. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003; (3): CD003293
9. Bokemeyer C, Franzke A, Hartmann JT, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80: 1221-7
10. Frustaci S, Buonadonna A, Galligioni E, et al. Increasing 4′-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study. J Clin Oncol 1997; 15: 1418-26
11. Reichardt P, Tilgner J, Hohenberger P, et al. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998; 16: 1438-43
12. Steward WP, Verweij J, Somers R, et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993; 11: 15-21
13. Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998; 21: 317-21
14. Benjamin RS, Legha SS, Patel SR, et al. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the MD Anderson experience. Cancer Chemother Pharmacol 1993; 31 Suppl. 2: S174-9
15. Gottlieb JA, Benjamin RS, Baker LH, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 1976; 60: 199-203
16. Balcerzak SP, Benedetti J, Weiss GR, et al. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas: a Southwest Oncology Group study. Cancer 1995; 76: 2248-52
17. Gallup DG, Blessing JA, Andersen W, et al. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2003; 89: 48-51
18. Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999; 86: 2034-7
19. van Hoesel QG, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult: EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1994; 5: 539-42
20. Kostler WJ, Brodowicz T, Attems Y, et al. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol 2001; 12: 1281-8
21. Edmonson JH, Ebbert LP, Nascimento AG, et al. Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol 1996; 19: 574-6
22. Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000; 18: 2081-6
23. Okuno S, Geyer SM, Maples WJ, et al. Phase 2 study of epothilone B analog (EMS-247550) in soft tissue sarcomas: an interim report [abstract no. 1645]. Proc Am Soc Clin Oncol 2002; 21: 412a
24. Spath-Schwalbe E, Genvresse I, Koschuth A, et al. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 2000; 11: 325-9
25. Svancarova L, Blay JY, Judson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38: 556-9
26. Okuno S, Edmonson J, Mahoney M, et al. Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002; 94: 3225-9
27. Okuno S, Ryan LM, Edmonson JH, et al. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 2003; 97: 1969-73
28. Hartmann JT, Oechsle K, Huober J, et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated advanced soft tissue sarcoma [abstract no. PO878]. J Cancer Res Clin Oncol 2004; 130: S192
29. Amodio A, Carpano S, Manfredi C, et al. Gemcitabine in advanced stage soft tissue sarcoma: a phase II study [in Italian]. Clin Ter 1999; 150: 17-20
30. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22: 890-9
31. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22: 1480-90
32. Hartmann JT, Oechsle K, Mayer F, et al. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res 2003; 23 (2C): 1899-901
33. Kollmannsberger C, Brugger W, Hartmann JT, et al. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs 1999; 10: 453-6
34. Blomqvist C, Wiklund T, Pajunen M, et al. Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma. Cancer Chemother Pharmacol 1995; 36: 263-5
35. Woll PJ, Judson I, Lee SM, et al. Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999; 35: 410-2
36. Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003; 98: 2693-9
37. Budd GT, Rankin C, Hutchins LF, et al. Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study: Southwest Oncology Group. Invest New Drugs 2002; 20: 129-32
38. Reichardt P, Oechsle K, Pink D, et al. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs 2003; 21: 481-6
39. Saylors III RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001; 19: 3463-9
40. Hosono A, Makimoto A, Kawamoto H, et al. A retrospective analysis in safety and efficacy of protracted administration of irinotecan for patients with small round cell sarcomas relapsed after stem cell transplantation (SCT) [abstract no. 3269]. Proc Am Soc Clin Oncol 2003; 22: 813
41. Pappo AS, Lyden E, Breitfeld PP, et al. Irinotecan (CPT-11) is active against pediatric rhabdomyosarcoma (RMS): a phase II window trial from the Soft Tissue Sarcoma Committee (STS) of the Children's Oncology Group (COG) [abstract no. 1570]. Proc Am Soc Clin Oncol 2002; 21: 393
42. De Angelo D, Naujoks R, Manola J, et al. Phase II study of irinotecan (CPT-11) in relapsed or refractory soft tissue sarcoma (STS) [abstract no. 2186]. Proc Am Soc Clin Oncol 2000; 19: 555a
43. Patel SR, Beach J, Papadopoulos N, et al. Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer 2003; 97: 2848-52
44. Fidias P, Demetri GD, Harmon D. Navelbine shows activity in previously treated sarcoma patients: phase II results from MGH/Dana Farber/Partner's Cancercare Study [abstract no. 1977]. Proc Am Soc Clin Oncol 1998; 17: 513a
45. Blay JY, Judson I, Rodenhuis S, et al. Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anti-cancer Drugs 1999; 10: 873-7
46. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20: 2824-31
47. Pivot X, Chevreau C, Cupissol D, et al. Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma. Am J Clin Oncol 2002; 25: 561-4
48. Casanova M, Ferrari A, Spreafico F, et al. Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 2002; 94: 3263-8
49. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001; 19: 3483-9
50. Van Glabbeke M, Verweij J, Judson I, et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543-9
51. Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients: preliminary evidence of activity. J Clin Oncol 2001; 19: 1248-55
52. Demetri GD. ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs 2002; 13 Suppl. 1: S7-9
53. Puchalski TA, Ryan DP, Garcia-Carbonero R, et al. Pharmaco-kinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002; 50: 309-19
54. Takahashi N, Li WW, Banerjee D, et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001; 7: 3251-7
55. Leahy MG, Blay JY, le Cesne A, et al. EORTC 62011: phase II trial of brostallicin for soft tissue sarcoma [abstract no. 694]. Eur J Cancer Suppl 2003; 1 (5): S209
56. Stevens MF, Hickman JA, Stone R, et al. Antitumor imidazotetrazines. 1: synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5- tetrazin-4(3 H)-one, a novel broad-spectrum antitumor agent. J Med Chem 1984; 27: 196-201
57. Tsang LL, Quarterman CP, Gescher A, et al. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, pro-drugs of 3-methyl-(triazen-l-yl) imidazole-4-carboxamide. Cancer Chemother Pharmacol 1991; 27: 342-6
58. Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47: 5846-52
59. Muro XD, Pousa AL, Buesa JM, et al. Temozolomide as a 6-week continuous oral schedule in advanced soft tissue sarcoma (STS): a phase II trial of the Spanish Group for Research on Sarcomas (GEIS) [abstract no. 1412]. Proc Am Soc Clin Oncol 2001; 20: 873
60. O'Reilly S, Rowinsky EK, Slichenmyer W, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996; 14: 3062-73
61. Bramwell VH, Eisenhauer EA, Blackstein M, et al. Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 1995; 6: 847-9
62. Wall ME, Wani MC, Natschke SM, et al. Plant antitumor agents: 22. Isolation of 11-hydroxycamptothecin from Camptotheca acuminata Decne: total synthesis and biological activity. J Med Chem 1986; 29 (8): 1553-5
63. Kharbanda S, Rubin E, Gunji H, et al. Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res 1991; 51: 6636-42
64. Natelson EA, Giovanella BC, Verschraegen CF, et al. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann N Y Acad Sci 1996; 803: 224-30
65. Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001; 23: 215-20
66. Tolcher AW, Eckhardt SG, Kuhn J, et al. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol 2001; 19: 2937-47
67. Bramwell VH, Morris D, Ernst DS, et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 2002; 8:383-93
68. Maki R, Kraft A, Demetri GD, et al. A phase II multicenter study of proteasome inhibitor PS-341 (LDP-341, bortezomib) for untreated recurrent or metastatic soft tissue sarcoma (STS); CTEP study 1757 [abstract no. 3291]. Proc Am Soc Clin Oncol 2003; 22: 819
69. Schoffski P, Thate B, Beutel G, et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 2004 Apr; 15 (4): 671-9
70. Debrock G, Vanhentenrijk V, Sciot R, et al. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 89: 1409-12
71. Li W, Fan J, Bertino JR. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res 2001; 61: 2579-82
72. Tomek S, Koestler W, Horak P, et al. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur J Cancer 2003; 39: 1318-29